Dimerix

Dimerix OCF/Debt

The Operating Cash Flow to Debt Ratio of Dimerix (DXB.AX) as of Oct 11, 2026 is -22,322.96 %. In the previous year, Operating Cash Flow to Debt Ratio was 40,061.64 % — a change of -155.72% (lower).

OCF/Debt

-22,322.96 %

YoY

-155.72%

Last updated:

Operating Cash Flow to Debt Ratio of Dimerix is 2026 -22,322.96 % . Operating Cash Flow to Debt Ratio of Dimerix was 2025 40,061.64 % . It decreases by -155.72% lower compared to the previous year.

The Dimerix OCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

OCF/Debt
Date
OCF/Debt
Jan 1, 2019
-251.37 AUD
Jan 1, 2020
-447.34 AUD
Jan 1, 2021
-126.89 AUD
Jan 1, 2022
-18,380.47 AUD
Jan 1, 2023
-213.68 AUD
Jan 1, 2024
-4,679.23 AUD
Jan 1, 2025
40,061.64 AUD
Jan 1, 2026
-22,322.96 AUD
The Dimerix OCF/Debt history
YEAROCF/DebtYoY
-22,322.96 %-155.72%
40,061.64 %-956.16%
-4,679.23 %+2,089.85%
-213.68 %-98.84%
-18,380.47 %+14,385.01%
-126.89 %-71.63%
-447.34 %+77.96%
-251.37 %—
Access this data via the Eulerpool API

Dimerix Stock analysis

What does Dimerix do? Dimerix Ltd is an Australian biotechnology company specializing in the development of innovative therapies for various medical needs. Their business model is based on identifying new targets for drug development, often through collaborations with other biotech or pharmaceutical companies. Dimerix focuses on cancer therapy, utilizing their innovative platform technology to identify and test a variety of drug candidates. They also have a pipeline of medications for kidney and lung diseases, as well as inflammation and pain. Dimerix actively seeks partnerships with other companies and research institutions to bring innovative therapies to market. One of their key products, DMX-200, is currently in phase II clinical trials for the treatment of kidney diseases and has shown promising results. Overall, Dimerix is well-positioned to continue bringing successful therapies to market in the future. Dimerix is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Dimerix stock

Operating Cash Flow to Debt Ratio of Dimerix is -22,322.96 % in 2026.

Operating Cash Flow to Debt Ratio of Dimerix changed from 40,061.64 % to -22,322.96 %, representing a -155.72% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Cash Flow to Debt Ratio Dimerix since 2006 – with annual values, charts, and detailed analysis.

OCF/Debt measures what percentage of total debt can be covered by annual operating cash flow. Higher ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Cash Flow to Debt Ratio's Dimerix with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

Leverage — Dimerix

All Key Metrics — Dimerix